We have a broad portfolio covering a wide range of therapeutic areas, and across modalities, from small molecules to cell therapy. Many have already attracted investments from top tier investors such as BB Pureos Bioventures, NEA, Syncona, Sofinnova, the Novartis Venture Fund, Biomedinvest, Boehringer Ingelheim Venture Fund, and others.
Developing novel inflammasome inhibitors.
Tag cell populations for removal or shielding. Better, safer safe bone marrow transplants and stem cell replacement.
First-in-class therapeutics to stop neurodegenerative diseases with a selective small molecule approach.